NFKB1 and pancreatic ductal adenocarcinoma: Findings from Shiah et al. support our hypothesis regarding NFκB-inhibition in pancreatic ductal adenocarcinoma (PDAC) cancer cell line, Panc-1, using the synthetic tylophorine analogue DCB-3503.